2025-12-18 08:30
Positioned for growth in Pharma Services and in the USA Q2 (August– October 2025) (comparison figures same period 2024) Q1 and Q2 (May – October 2025) (comparison figures same period 2024) Significant events during Q2 (August – October...
2025-12-15 08:30
Biovica, a leader in blood-based cancer monitoring, today announced that the company has entered into a commercial agreement (client bill agreement) with a leading U.S. NCI-designated Comprehensive Cancer Center. The agreement enables clinicians at the...
2025-11-26 08:45
Biovica, a leader in blood-based cancer monitoring, today announces the presentation of two new abstracts at the 2025 San Antonio Breast Cancer Symposium (SABCS). Both studies highlight the clinical relevance of DiviTum® TKa as a dynamic biomarker...
2025-09-23 12:00
The annual general meeting of Biovica International AB ("Biovica" or the "Company") was held today on 23 September 2025 and the following resolutions were passed by the meeting. Adoption of the income statement and balance sheetThe...
2025-09-11 08:00
Partnership agreement with Tempus and continued organic growth in the USA Biovica in brief – Treatment decisions with greater certainty FNCA Sweden AB is the company’s Certified Adviser. For more information, please visit: www.biovica.com...
2025-08-22 08:00
The shareholders of Biovica International AB, reg. no. 556774-6150 (the "Company"), are hereby invited to the annual general meeting to be held on Tuesday 23 September 2025, at 10.00 CEST at Conference Hubben, Dag Hammarskjölds Väg...
2025-08-13 17:35
NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS...
2025-08-05 14:00
NOT TO BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, THE UNITED STATES OF AMERICA, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS...
2025-07-25 08:00
Biovica, active in blood-based cancer monitoring, today announces the launch of DiviTum Tka for use in early breast cancer for patients undergoing adjuvant therapy, available as a laboratory developed test (LDT) from its CLIA-certified laboratory in the...
2025-07-24 08:00
Biovica, a leader in blood-based cancer monitoring, today announced its fourth’s work order with this Tier-1 pharmaceutical customer. This order is valued at approximately SEK 3 million. The project is expected to be fully executed during fall 2025...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects